Literature DB >> 3030070

The Lewy body in Parkinson's disease.

L S Forno.   

Abstract

In this brief overview three problems regarding Lewy bodies have been taken up for discussion: the specificity of the Lewy bodies, the extranigral sites for the inclusions, and the variable morphology and composition of the bodies in different portions of the nervous system. These questions go to the heart of the problem of nerve cell degeneration in Parkinson's disease. The question about the specificity of Lewy bodies has been answered in the affirmative. It therefore is worthwhile to examine the Lewy bodies, find out what they are composed of, and what molecular events precede and accompany their formation. Once we know that, will we be able to prevent Lewy bodies from forming? And if Lewy bodies do not form, will we then have no substantia nigra degeneration and no Parkinson's disease? Perhaps that is too much to expect from Lewy's peculiar cellular inclusions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3030070

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  28 in total

1.  Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material.

Authors:  B Lach; D Grimes; B Benoit; A Minkiewicz-Janda
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

Review 2.  Transplantation into the human brain: present status and future possibilities.

Authors:  O Lindvall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

3.  Ca2+/calmodulin-dependent protein kinase II immunoreactivity in Lewy bodies.

Authors:  T Iwatsubo; I Nakano; K Fukunaga; E Miyamoto
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 4.  Pattern of brain destruction in Parkinson's and Alzheimer's diseases.

Authors:  H Braak; E Braak; D Yilmazer; R A de Vos; E N Jansen; J Bohl
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease.

Authors:  G Lennox; J Lowe; K Morrell; M Landon; R J Mayer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

6.  Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry.

Authors:  G Lennox; J Lowe; M Landon; E J Byrne; R J Mayer; R B Godwin-Austen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-11       Impact factor: 10.154

7.  Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study.

Authors:  S Kuzuhara; H Mori; N Izumiyama; M Yoshimura; Y Ihara
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

8.  Spinal cord involvement in Lewy body-related α-synucleinopathies.

Authors:  Raffaele Nardone; Yvonne Höller; Francesco Brigo; Viviana Versace; Luca Sebastianelli; Cristina Florea; Kerstin Schwenker; Stefan Golaszewski; Leopold Saltuari; Eugen Trinka
Journal:  J Spinal Cord Med       Date:  2019-01-08       Impact factor: 1.985

9.  Amygdala pathology in Parkinson's disease.

Authors:  H Braak; E Braak; D Yilmazer; R A de Vos; E N Jansen; J Bohl; K Jellinger
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 10.  Different diagnostic criteria for Parkinson disease: what are the pitfalls?

Authors:  Roongroj Bhidayasiri; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2013-03-15       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.